From bench to bedside and beyond in cancer prevention – the example of resveratrol
Professor Karen Brown (University of Leicester)
OS6, Oakfield House, BS8 2BN and online
Hosted by the Integrative Cancer Epidemiology Programme
Bio: Karen originally trained as a pharmacist and is currently Professor of Translational Cancer Research at the University of Leicester, where she leads the multidisciplinary Cancer Prevention Group. She has an emphasis on using clinically relevant models, such as primary explant cultures, informed by reverse translation of trials results. She also has an interest in the role of metabolic health in cancer development and how this interacts with preventive therapies to influence efficacy. Her research over the last 20 years has culminated in her securing Cancer Research UK funding for COLO-PREVENT, a world first prevention trial platform of resveratrol, aspirin and metformin in high-risk patients, which will be conducted across 60 sites and includes an embedded programme of translational research focussed on precision prevention.
Karen is joint lead of the Leicester Experimental Cancer Medicine Centre and Director of the Leicester Cancer Research Centre. She established and is co-Chair of the UK Therapeutic Cancer Prevention Network and represents this Network on the steering group of the Cancer Prevention Europe Consortium; she is also Vice-Chair of the Cancer Research UK Prevention and Population Research Committee.
If joining online: https://bristol-ac-uk.zoom.us/j/94066361494?pwd=TlErYW5laHpZaU1mOTZ4K3U5UktXQT09
Contact information
Enquiries to Lucy Hartfield